These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14656255)

  • 21. Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.
    Fajardo J; Heywood JT; Patterson JH; Adams K; Chow SL
    Expert Rev Cardiovasc Ther; 2015; 13(7):743-51. PubMed ID: 26028173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current pharmacologic management of pediatric heart failure in congenital heart disease.
    Bautista-Hernandez V; Sanchez-Andres A; Portela F; Fynn-Thompson F
    Curr Vasc Pharmacol; 2011 Sep; 9(5):619-28. PubMed ID: 21314633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nesiritide--not verified.
    Schreiner G
    N Engl J Med; 2005 Oct; 353(14):1525-7; author reply 1525-7. PubMed ID: 16211709
    [No Abstract]   [Full Text] [Related]  

  • 25. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 26. Heart failure. Tardy but intact--publication of REVIVE trial results welcomed.
    Cully M
    Nat Rev Cardiol; 2013 Jun; 10(6):297. PubMed ID: 23609172
    [No Abstract]   [Full Text] [Related]  

  • 27. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 28. Heart failure update.
    Gomes UC; Cleland JG
    Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
    Büyüklü M; Kürüm AT; Tatlý E; Set T
    Arq Bras Cardiol; 2012 Jul; 99(1):659-64. PubMed ID: 22735864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
    Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan in patients with decompensated heart failure.
    Rosa EM; Osório AP; Scopel L
    Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
    [No Abstract]   [Full Text] [Related]  

  • 32. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis.
    Ribeiro RA; Rohde LE; Polanczyk CA
    Arq Bras Cardiol; 2010 Aug; 95(2):230-7. PubMed ID: 20549133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
    Greenberg B; Borghi C; Perrone S
    Eur J Heart Fail; 2003 Jan; 5(1):13-21. PubMed ID: 12559210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
    Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R
    Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic stabilization and management of acute heart failure syndromes in the emergency department.
    Kirk JD; Parissis JT; Filippatos G
    Heart Fail Clin; 2009 Jan; 5(1):43-54, vi. PubMed ID: 19026385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BELIEF: believe it or not.
    Beck-da-Silva L; Fuchs FD
    Arq Bras Cardiol; 2008 Aug; 91(2):119-21. PubMed ID: 18709264
    [No Abstract]   [Full Text] [Related]  

  • 37. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 38. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
    Parissis JT; Farmakis D; Kremastinos DT
    Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844
    [No Abstract]   [Full Text] [Related]  

  • 39. Levosimendan and pulmonary hypertension.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):478-80. PubMed ID: 20516805
    [No Abstract]   [Full Text] [Related]  

  • 40. Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
    Kivikko M; Sundberg S; Karlsson MO; Pohjanjousi P; Colucci WS
    Scand Cardiovasc J; 2011 Apr; 45(2):86-90. PubMed ID: 21133820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.